Point Therapeutics Announces Preclinical Data Presentations at Upcoming American Association of Cancer Research Annual Meeting
April 13 2007 - 7:00AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) today reported the upcoming
presentation of preclinical data at the 2007 Annual Meeting of the
American Association for Cancer Research (AACR) taking place in Los
Angeles, California, April 14-18, 2007. The AACR poster
presentations report on preclinical studies on talabostat�s novel
mechanism of action. Additional details for the AACR presentations
are as follows: Presentation Date and Time: Monday, April 16, 2007,
8:00 AM -12:00 PM PT Abstract #1894: Immune mechanisms of action of
talabostat: a dipeptidyl peptidase targeted anti-tumor agent
Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM
-12:00 PM PT Abstract #5622: The anti-tumor potential of inhibitors
of the DASH proteases in a mouse model of human breast cancer The
posters associated with the abstracts will be available on the
Point Therapeutics� web site at www.pther.com immediately following
their presentation. About Point Therapeutics, Inc.: Point is a
Boston-based biopharmaceutical company currently studying its lead
product candidate, talabostat, in two Phase 3 double blind,
placebo-controlled trials in non-small cell lung cancer and in a
Phase 2 trial in combination with gemcitabine in metastatic
pancreatic cancer. Point has also studied talabostat in several
Phase 2 trials, including as a single-agent in metastatic melanoma,
in combination with cisplatin in metastatic melanoma and in
combination with rituximab in advanced chronic lymphocytic
leukemia.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles